We conclude that an orally absorbed, cell permeable inhibitor of neutrophil elastase, if proven safe and effective in a clinical trial, is a good alternative to G-CSF or gene editing to treat ELANE neutropenia. Here, CSF3 is linked to Decreased total neutrophil count.